UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.
UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.